Hints and tips:
...A potentially bigger opportunity is pharmaceuticals: a pre-IPO investment deck still available on the SpectrumX website says the company “holds licenses for both the UK and EU pharmaceutical application...
...“The art and challenge of developing nanoparticles is to combine lipids with different physical characteristics in a way that stabilises the RNA as effectively as possible,” said Mike Watson, a former head...
...“It’s the biggest vaccine programme in history and the logistics are enormous,” said Dr Nigel Watson, chief executive of the Wessex Local Medical Committees....
...The pharmaceutical and healthcare sectors have been among the most active with $479bn worth of transactions announced....
...It was once a Wall Street darling, executing an inversion deal with Actavis and other aggressive acquisitions. As its growth prospects slowed, investors grew restless....
David Tepper’s Appaloosa hedge fund had been instigating for change
...A former Bausch & Lomb executive, the 49-year-old built Allergan through a succession of deals that began in 2013 when the company he ran, then called Actavis, bought Ireland-headquartered Warner Chilcott...
...Boots’ beauty business has been under attack from traditional rivals — supermarkets, discount stores and direct competitors such as Superdrug, which is backed by Li Ka-shing’s AS Watson retail business....
...The firm’s original investment in Allergan was a money-spinner, reaping gains of $2.3bn before the company agreed a sale to Actavis....
...Actavis Holdco U.S., Inc.; Actavis Pharma, Inc.; Ascend Laboratories, LLC; Apotex Corp.; Dr....
...Watson Pharmaceuticals and Par Pharmaceutical have previously been prevented from working on a generic film alternative, but Indivior said the latest ruling means they “are now able to pursue their respective...
...Allergan received a 10 per cent stake, or 100m shares, in Teva last year after it agreed to sell its generics business Actavis to the Israeli drugmaker last year....
...ValueAct has previously agitated for management changes at Rolls-Royce, and driven merger and acquisition activity at groups as diverse as Valeant Pharmaceuticals and insurance broker Willis Towers Watson...
...The relevant SEC filings were made by Allergan, Inc. prior to its acquisition by Actavis plc....
...Teva Pharmaceuticals showed the way in 2015 when it announced it was buying Gecko Health Innovations for an undisclosed sum....
...The closely watched case not only opens up the medicine to more competition in the UK, but tests the ability of pharmaceuticals companies to defend patents for “secondary uses” after they lose market exclusivity...
...At Allergan, however, he said he was “very supportive” of Mr Saunders, a powerful player in the pharmaceuticals industry’s recent frenzy of dealmaking....
...In 2013 Ireland-based Warner Chilcott bought US-based Actavis, then in 2015, Actavis bought US-based Allergan....
...The US competition watchdog is suing Endo Pharmaceuticals and several other drugmakers for agreeing “pay for delay” deals worth hundreds of millions of dollars to stall rivals’ introduction of cheaper generic...
...Allergan, previously known as Actavis, was itself one of numerous lesser-known US companies to have “redomiciled” to Ireland or other lower-tax countries....
...That transaction transformed the company, then known as Actavis, from a manufacturer of generic copycat medicines into a branded drugmaker. “Brent is a bold guy,” says one investor....
...Dechra Pharmaceuticals, the veterinary medicines maker, was down 3.7 per cent to £11.34 after Jefferies restarted coverage with “hold” advice....
...In 2013, US-based Actavis bought Ireland-headquartered Warner Chilcott, paving the way for the company to relocate its tax base away from the US and paved the way for a series of aggressive acquisitions...
...Allergan (formerly known as Actavis and before that as Watson) describes itself as pioneering a new model in the drug sector....
International Edition